Key Highlights

  • MTVA reported a Q3 net loss of US$4,623 thousand, or US$0.69 per share.
  • Research and development expenses were US$2,589 thousand versus US$1,914 thousand.
  • DA-1726 direct research costs were US$1,932 thousand versus US$1,080 thousand.
  • Cash and cash equivalents totaled US$8.8 million at September 30, 2026.

MTVA filed its Quarterly Report on November 13, 2026, for the three and nine months ended September 30, 2026. Total operating expenses were US$4,693 thousand, versus US$3,475 thousand, an increase of 35.1%. Research and Development expenses were US$2,589 thousand, an increase of US$0.7 million, or 35.3%, and general and administrative expenses were US$2,104 thousand, an increase of US$0.5 million, or 34.8%.

The company tied the research increase to activity for the Phase 1 clinical trial of DA-1726, primarily higher direct DA-1726 development costs, partly offset by US$0.2 million of lower indirect consulting expenses.

Research Cost Detail and Net Loss

Direct research costs were US$205 thousand for vanoglipel versus US$190 thousand, US$1,932 thousand for DA-1726 versus US$1,080 thousand, and US$13 thousand for other research versus US$52 thousand. Indirect costs included employee compensation and benefits of US$386 thousand versus US$351 thousand and consulting of US$53 thousand versus US$241 thousand. Direct costs included US$0.3 million versus US$0.2 million for investigational drug manufacturing, non-clinical and preclinical costs under a Shared Services Agreement with Dong-A ST, a related party.

Loss from operations was US$(4,693) thousand versus US$(3,475) thousand. The change in Fair Value of Warrant liabilities was a loss of US$(2) thousand versus US$(53) thousand, and interest income, net, was US$72 thousand versus US$151 thousand. Net loss was US$(4,623) thousand, or US$(0.69) per share, versus US$(3,377) thousand, or US$(1.52). Weighted average shares were 6,679,250 versus 2,219,625.

For the nine months, research and development expenses were US$8,168 thousand versus US$6,561 thousand, and general and administrative expenses were US$5,935 thousand versus US$5,101 thousand. Net loss was US$(13,762) thousand, or US$(2.36) per share, versus US$(11,043) thousand, or US$(6.93).

January Offering, Warrants and Cash

The company said cash and cash equivalents totaled US$8.8 million at September 30, and that it has funded operations primarily through public offerings of common stock and private placements of Equity and convertible securities. In January 2026 it closed an underwritten public offering with net proceeds of US$7.1 million, selling 1,006,870 Class A Units at US$3.10 and 1,998,704 Class B Units at US$3.099, each unit carrying 1.5 Series C and 1.5 Series D common warrants.

Each Series C and Series D warrant has an exercise price of US$3.10 per share and is immediately exercisable, expiring on January 16, 2031 and January 16, 2028, respectively. The company said the Series D warrants are callable at its option following a data readout for its Phase 1, Part 3 clinical trial of DA-1726 announced by widely disseminated press release, subject to conditions. In the nine months, 1,998,704 January 2026 pre-funded warrants and 30,039 January 2026 Series C warrants were exercised.

Quarter in Review: Trial Activity and Funding

MTVA's third quarter combined higher DA-1726 trial spending and higher administrative costs with a net loss of US$4,623 thousand and cash of US$8.8 million. The company said its primary use of cash is to fund research and development activities.